Soliris/Ultomiris
PreclinicalSmall molecule
AstraZenecaSoliris/Ultomiris is one of 32 small molecule programs targeting Paroxysmal Nocturnal Hemoglobinuria. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Paroxysmal Nocturnal Hemoglobinuria
#DrugCompanyPhaseTrials
1VEOPOZ
RegeneronPhase 3
Fabhalta
NovartisPhase 3
Cemdisiran
RegeneronPhase 3
Empaveli
Apellis PharmaceuticalsPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
PIASKY
RochePhase 2
LNP023
NovartisPhase 2
Glucocorticoids
NovartisPhase 2
LFG316
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Soliris/Ultomiris. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company